Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.
about
MPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsImpact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentPathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationVenous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Ruxolitinib versus standard therapy for the treatment of polycythemia vera.A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisWhole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.Mechanisms of thrombogenesis in polycythemia veraThe impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasmsBiomarkers of chronic inflammatory state in uremia and cardiovascular disease.Novel and emerging therapies for the treatment of polycythemia veraThe efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.How to manage essential thrombocythemia.The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Are MPNs vascular diseases?The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?An immune dysregulation in MPN.Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.Ruxolitinib for the treatment of patients with polycythemia vera.Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease.Investigation of T-cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) polymorphisms in essential thrombocythaemia (ET).Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.Smoking and philadelphia-negative chronic myeloproliferative neoplasms.Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study.Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer developmentAnnual decline in pentraxin 3 is a risk of vascular access troubles in hemodialysis patients.Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond.Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.Myocardial infarction as a thrombotic complication of myeloproliferative disorders.Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.Pathophysiology of thrombosis in myeloproliferative neoplasms.Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis.The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
P2860
Q26775996-61288A21-FC6D-4BBC-A25A-A353832DAF3CQ26777398-DCA6A701-939C-4D2B-BD5A-94E8549D8763Q26779929-0D0225D4-FF78-4260-B117-861C936D9FC6Q26779947-6B121672-4661-4184-A34C-563C0361AA93Q26779960-F8CF1B37-662F-439F-8A60-E6FF5C5C444CQ33398180-1E68C461-36D8-4174-88D2-7CFC5E684175Q33420037-E136840C-09D0-410E-AF95-39BE9CA58DC9Q33434284-5F3BBA10-EB32-4C3B-8072-DD5834D773B1Q34514329-52609744-D7D2-44B5-A0DC-9009E4AE9404Q35738656-9BFF27F1-A3A4-4C8E-AFB2-1B865AF15DFCQ35841839-85E4C71F-0067-45B0-AC84-3E96FC7B8AF4Q36026534-21B46545-526E-4476-9C0F-213D2DA2D11CQ37069633-30DE81CC-8560-4D19-A0A4-E83B1CD7310DQ37561170-D1A14139-3B38-4104-8008-E3AE84DB5B95Q37661411-8B772345-63CA-4AD6-A0A9-6BC9AA631B92Q37952488-736A1819-0185-49F4-B3D0-8563429B066BQ38092832-0C84F7AC-A627-4885-B6B9-2776DB4809AAQ38100371-059576BD-9F09-431B-B345-77C2DD4F757EQ38137750-243F7174-2E8C-4800-A73B-18A1494B99EDQ38239580-351668DF-A026-440B-BFDD-A602F6797A2CQ38241495-EA21B538-6AC6-4FDA-B7E3-2B860C755479Q38255717-B07D50A6-E3D9-4E87-8FF2-FB4F5F013882Q38484321-F42344E2-95A3-4CE6-BA5B-BDE8C0452E24Q38706624-668F35A9-FEBD-47B2-A508-E12171485223Q38725723-C60C7828-720B-422C-B933-2B1ADD99A6EFQ39108026-4B0A5DFE-515B-4A09-B20D-9BB86A3A4842Q40418741-D2F8363F-6486-487E-BA98-267F5C521D23Q41095829-FD7A304A-F635-4D03-A34F-7F64D40ADFB2Q41348010-66F79F20-4A55-448B-8154-7E1617C6F4F9Q41560568-579C7B4A-FB9A-4E16-ABB6-5D776C86337CQ41576528-0BC5C393-46FC-4F52-B3B9-6BC0CEBCCFACQ41839109-E4015810-DDF8-4C5E-BC81-12ECA2CBD14EQ42072780-C678DFA0-B9EC-4D44-BAB6-3963C3ACF6ACQ42221121-97878F42-24F4-4009-80EB-7641108C65ACQ42319131-81AB1D26-891A-4799-8D08-0AC170D3CBF2Q42505998-60BA1147-C21B-4B4A-B65F-7E3DE55B9A32Q42586757-E813D567-BCF5-4E0E-8E29-314571B09460Q42743763-0C08FAE2-64C6-4F3E-8E81-181C5D33FEC4Q42958719-AEFBDDA5-2B0B-48A7-9A45-DCCE50E6604CQ45738285-0E861D2B-FEA2-4E5A-8CFF-743302CF92D4
P2860
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@ast
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@en
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@nl
type
label
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@ast
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@en
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@nl
prefLabel
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@ast
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@en
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@nl
P2093
P2860
P50
P1433
P1476
Inflammation and thrombosis in ...... ctive protein and pentraxin 3.
@en
P2093
AGIMM and IIC Investigators
Alessandra Carobbio
Alessandro M Vannucchi
Alessandro Rambaldi
Cosimo Ottomano
Elisabetta Antonioli
Giovanni Barosi
Guido Finazzi
Ivan Cuccovillo
P2860
P304
P356
10.3324/HAEMATOL.2010.031070
P577
2010-12-20T00:00:00Z